NCT04743505View on ClinicalTrials.gov

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

May 31, 2030

Conditions

Metastatic Non Small Cell Lung Cancer

Interventions

DRUG

APL-101

-Provided by Apollomics

DRUG

Osimertinib

-Given standard of care

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Apollomics Inc.

All Listed Sponsors

collaborator

Apollomics Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER